行情

CEMI

CEMI

Chembio诊断
NASDAQ

实时行情|Nasdaq Last Sale

5.60
+0.44
+8.53%
盘后: 5.60 0 0.00% 19:36 03/27 EDT
开盘
5.28
昨收
5.16
最高
5.79
最低
5.07
成交量
91.82万
成交额
--
52周最高
7.90
52周最低
2.250
市值
9,930.83万
市盈率(TTM)
-6.9678
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CEMI价格均价为7.25,最高价位10.00,最低价为5.00。

EPS

CEMI 新闻

更多
  • Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire · 03/20 13:30
  • Biotech and hospitality stocks among premarket gainers
  • Seeking Alpha - Article · 03/20 13:22
  • Chembio Diagnostics Receives $4 Million Purchase Order from Bio-Manguinhos for Production of DPP COVID-19 IgM/IgG System in Brazil
  • GlobeNewswire · 03/20 13:00
  • Chembio up 31% premarket on big order for Covid-19 test
  • Seeking Alpha - Article · 03/20 12:17

所属板块

制药
-0.41%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

CEMI 简况

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
展开

微牛提供Chembio Diagnostics Inc(NASDAQ-CEMI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CEMI股票新闻,以帮助您做出投资决策。